

**Specimen Collected: 15-Dec-23 12:18**

**Adalimumab/Ab to Adalimumab Quantitation** | **Received: 15-Dec-23 12:18** | **Report/Verified: 15-Dec-23 12:20**

Procedure	Result	Units	Reference Interval
Adalimumab Quantitation	<0.4 <sup>L i1</sup>	ug/mL	[>=0.4]
Antibodies to Adalimumab Quantitation	160 <sup>H i2</sup>	ng/mL	[<=19]

**Test Information**

i1: Adalimumab Quantitation  
 INTERPRETIVE INFORMATION: Adalimumab Quantitation

Results of 0.4 ug/mL or higher indicate the detection of adalimumab or an adalimumab biosimilar. Therapeutic level may vary depending on the disease being treated.

i2: Antibodies to Adalimumab Quantitation  
 INTERPRETIVE INFORMATION: Antibodies to Adalimumab Quantitation

Results of 20 ng/mL or higher indicate the detection of antibodies against adalimumab or an adalimumab biosimilar. Interpret in the context of adalimumab or adalimumab biosimilar trough concentration to determine clinical significance and impact on treatment efficacy.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

\*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab

**Unless otherwise indicated, testing performed at:**

**ARUP Laboratories**

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

**ARUP Accession:** 23-349-900064

**Report Request ID:** 18509749

**Printed:** 18-Dec-23 09:13